Capital/Financing Update • Jul 20, 2020
Capital/Financing Update
Open in ViewerOpens in native device viewer

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
As of June 30, 2020, the following assets appeared on the liquidity account:
As of July 8, 2018, upon signing of the liquidity contract, the following resources appeared on the liquidity account:
24,313 DBV Technologies ordinary shares; € 682 454,94
Number of transactions executed during the first half-year 2020:
Over the same period, the volumes traded represented:
DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut (DBV712). DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each

representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.